INmune Bio Inc. (INMB)

Market Cap	30.04M -82.7%
Revenue (ttm)	50,000 +257.1%
Net Income	-45.93M
EPS	-1.86
Shares Out	26.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	460,304
Open	1.110
Previous Close	1.140
Day's Range	1.090 - 1.155
52-Week Range	1.090 - 11.640
Beta	0.85
Analysts	Buy
Price Target	5.40 (+377.88%)
Earnings Date	Mar 30, 2026

About INMB

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2019
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: INMB
• Website: https://www.inmunebio.com

Financial Performance

In 2025, INmune Bio's revenue was $50,000, an increase of 257.14% compared to the previous year's $14,000. Losses were -$45.93 million, 9.15% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for INMB stock is "Buy." The 12-month stock price target is $5.4, which is an increase of 377.88% from the latest price.

Price Target

$5.4

(377.88% upside)

Analyst Consensus: Buy